AI assistant
Galapagos NV Major Shareholding Notification 2021
3954_mrq_2021-03-03_4acca214-78ba-4002-8957-c4ea528cb0d8.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
Transparency notification received from The Capital Group
Mechelen, Belgium; 3 March 2021; 22.15 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc.
Pursuant to Belgian transparency legislation1 , Galapagos received a transparency notification on 26 February 2021 from The Capital Group Companies, Inc., who notified that it holds 9.91% of the current 65,411,767 outstanding Galapagos shares. The Capital Group Companies, Inc. thus crossed below the 10% threshold of Galapagos' voting rights by disposing of voting securities on 22 February 2021. The full transparency notice is available on the Galapagos website.
About Capital Group
Capital Group controls Capital Bank & Trust Company and Capital Research & Management Company through its direct subsidiary Capital Group International, Inc. ("CGII"), controls four CGII investment management companies (Capital International, Inc.; Capital International Limited, Capital International Sàrl; and Capital International K.K.), which all together hold 6,483,973 of Galapagos' voting rights, consisting of ordinary shares, which represents 9.91%.
About Galapagos
Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
Contacts
Investors: Elizabeth Goodwin VP Investor Relations +1 781 460 1784
Sofie Van Gijsel Senior Director Investor Relations +32 485 19 14 15 [email protected]
Media:
Carmen Vroonen Global Head Communications & Public Affairs +32 473 824 874
Anna Gibbins Senior Director Therapeutic Areas Communications +44 7717 801900 [email protected]
1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market